Fig. 2From: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysisRelative risk for clinical pregnancy rate (a), ongoing pregnancy rate (b) and ovarian hyperstimulation syndrome (c) with biosimilar preparations of follitropin alfa versus the reference productBack to article page